WESTBOROUGH, Mass.,
Feb. 24, 2014 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering, developing and
commercializing innovative therapies addressing major unmet medical
needs using RNA-targeted technologies, today announced that the
Company's President & CEO, Dr. Geert
Cauwenbergh, will present at the 24th Annual Wall
Street Analyst Forum on Monday, March 3,
2014 at 12:50pm EST. Dr.
Cauwenbergh will discuss the development of RXI-109, a
self-delivering RNAi compound designed to reduce dermal scarring,
as well as business development opportunities with RXi's sd-rxRNA®
technology platform.
(Logo:
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO )
The webcast presentation will be available on the "Investors"
section of the Company's website, www.rxipharma.com.
Since 1989, The Wall Street Analyst Forum has been a leading
sponsor of institutional investor conferences in New York, Boston and London. Over 2200 corporations, from General
Electric, Pfizer, Mattel and Nokia, have presented with more than
2000 institutional investors from money management firms in
attendance. The conference will take place March 3-4, 2014 at the University Club of New
York City. For further information, please visit
www.analyst-conference.com.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their
ability to down-regulate the expression of a specific gene that may
be over-expressed in a disease condition. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, targets connective tissue growth factor (CTGF) to reduce
dermal scarring (fibrosis), entered into human clinical trials in
June 2012. For more information, please visit
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks, and uncertainties:
risks that RXi may not be able to successfully develop its
candidates, or that development of RNAi-based therapeutics may be
delayed or not proceed as planned, or that we may not develop any
RNAi-based product; risks that the development process for our
product candidates may be delayed, risks related to development and
commercialization of products by our competitors, risks related to
our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation